MedPlus Health Services Limited (NSE:MEDPLUS)
India · Delayed Price · Currency is INR | Market Cap | 96.24B -13.3% |
| Revenue (ttm) | 68.92B +12.3% |
| Net Income | 2.20B +46.1% |
| EPS | 18.29 +46.1% |
| Shares Out | 120.14M |
| PE Ratio | 43.80 |
| Forward PE | 36.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 68,286 |
| Open | 809.75 |
| Previous Close | 808.95 |
| Day's Range | 798.95 - 817.55 |
| 52-Week Range | 732.00 - 1,022.20 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 1,168.71 (+45.89%) |
| Earnings Date | Jul 21, 2026 |
About MedPlus Health Services
MedPlus Health Services Limited engages in the retail trading of medicines and general items in India. It manufactures and trades in pharmaceutical and wellness products, such as prescription medicines, over-the-counter drugs, vitamins, medical devices, and diagnostic test kits; and fast-moving consumer goods (FMCG), including personal and home care products like toiletries, baby care items, soaps, detergents, and sanitizers. The company also engages in wholesale cash and carry; provision of diagnostic, pathological, and laboratory testing serv... [Read more]
Financial Performance
In fiscal year 2026, MedPlus Health Services's revenue was 68.92 billion, an increase of 12.33% compared to the previous year's 61.36 billion. Earnings were 2.20 billion, an increase of 46.12%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for MEDPLUS stock is "Strong Buy." The 12-month stock price target is ₹1,169, which is an increase of 45.89% from the latest price.
News
MedPlus Health Services Transcript: Q4 25/26
Q4 saw strong revenue and EBITDA growth, with 218 net new stores and a total of 5,330 outlets. Private label sales stabilized at 22% of revenue, and the franchisee model expanded to over 500 stores, delivering immediate profitability. Management expects to maintain margins and continue network expansion.
MedPlus Health Services Quarterly report: Q4 2026
MedPlus Health Services has published its Q4 2026 quarterly earnings report on May 21, 2026.
MedPlus Health Services Slides: Q4 2026
MedPlus Health Services has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 21, 2026.
MedPlus Health Services Transcript: Q3 25/26
Q3 FY26 saw robust revenue and EBITDA growth, strong store expansion, and a rising private label mix. Margins remained stable despite a one-off labor code charge, and management expects continued growth in stores and profitability, driven by private label and operational efficiencies.
MedPlus Health Services Quarterly report: Q3 2026
MedPlus Health Services has published its Q3 2026 quarterly earnings report on February 2, 2026.
MedPlus Health Services Slides: Q3 2026
MedPlus Health Services has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on February 2, 2026.
MedPlus Health Services Transcript: Q2 25/26
Q2 FY26 saw 145 new stores added, revenue up 8.8% YoY, and private label sales at 21.5% of total. Diagnostic EBITDA margin improved to 15.3%. SSSG turned positive at 2.2%, with high single-digit growth targeted in two years.
MedPlus Health Services Quarterly report: Q2 2026
MedPlus Health Services has published its Q2 2026 quarterly earnings report on November 3, 2025.
MedPlus Health Services Slides: Q2 2026
MedPlus Health Services has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on November 3, 2025.
MedPlus Health Services Transcript: Q1 25/26
Revenue grew 6.6% YoY on GMV with pharmacy EBITDA margin at 4.6%. Private label share rose to 20.4%, supporting margin expansion, while 101 net new stores were added. Diagnostic segment showed strong growth, but further expansion awaits higher membership.
MedPlus Health Services Quarterly report: Q1 2026
MedPlus Health Services has published its Q1 2026 quarterly earnings report on August 4, 2025.
MedPlus Health Services Slides: Q1 2026
MedPlus Health Services has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on August 4, 2025.